Macrogenics Inc. | Key People and Executives
Scott E. Koenig
President, Chief Executive Officer & Director
Jay Philip Siegel
Independent Director
Scott T. Jackson
Independent Director
Karen Jean Ferrante
Independent Director
David C. Stump
Independent Director
Kenneth H. Galbraith
Independent Director
Ed M. Hurwitz
Independent Director
Matthew K. Fust
Independent Director
Scott E. Koenig
President, Chief Executive Officer & Director
James Karrels
Chief Financial Officer, Secretary & Senior VP
Ezio Bonvini
Chief Scientific Officer & Senior VP-Research
Jon Wigginton
Chief Medical Officer & SVP-Clinical Development
Eric Risser
Chief Business Officer & SVP-Business Development
Thomas M. Spitznagel
SVP-BioPharmaceutical Development & Manufacturing
Syd Johnson
Vice President-Antibody Engineering
Robert Dallimore
Vice President-Quality
Paul A. Moore
Vice President-Immunology & Cell Biology
Lynn Cilinski
Treasurer, CAO, Vice President & Controller
Robert Obst
Vice President-Human Resources & Facilities
Jeffrey Peters
Vice President & General Counsel
Jay Philip Siegel
Independent Director
Scott T. Jackson
Independent Director
Karen Jean Ferrante
Independent Director
David C. Stump
Independent Director
Kenneth H. Galbraith
Independent Director
Ed M. Hurwitz
Independent Director
Matthew K. Fust
Independent Director
| Address |
9740 Medical Center Drive
Rockville Maryland 20850
United States
|
|
Employees
|
- |
| Website |
http://www.macrogenics.com |
| Updated |
07/08/2019 |
| MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its portfolio includes Margetuximab, Flotetuzumab, MGA012, MGD013, Enoblituzumab, MGD009, and Teplizumab. The company was founded by Scott E. |
